[CAS NO. 1374248-81-3] Atogepant
PRODUCTS SPECIFICATIONS [1374248-81-3]
DESCRIPTION [1374248-81-3]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 603.52 |
| Molecular Formula | C29H23F6N5O3 |
| SMILES | O=C1[C@]2(CC3=CC(C(N[C@H]4C[C@](C5=C(C(F)=CC=C5F)F)([H])[C@H](N(C4=O)CC(F)(F)F)C)=O)=CN=C3C2)C6=CC=CN=C6N1 |
Summary
Atogepant (MK-8031) is an orally active and selective calcitonin gene–related peptide receptor (CGRP) antagonist. Atogepant can be used for researching migraine [1] .
IC50 & Target
CGRP [1]
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT03855137 | Allergan |
Chronic Migraine
|
March 11, 2019 | Phase 3 |
| NCT04437433 | Allergan |
Chronic Migraine|Episodic Migraine
|
June 18, 2020 | Phase 3 |
| NCT02848326 | Allergan |
Migraine, With or Without Aura
|
September 6, 2016 | Phase 2|Phase 3 |
| NCT04829747 | Allergan |
Chronic Migraine
|
August 2, 2021 | Phase 3 |
| NCT03777059 | Allergan |
Episodic Migraine
|
December 14, 2018 | Phase 3 |
| NCT04818515 | AbbVie |
Migraine
|
March 17, 2021 | Phase 1 |
| NCT04686136 | Allergan |
Episodic Migraine|Chronic Migraine
|
February 19, 2021 | Phase 3 |
| NCT04740827 | Allergan |
Episodic Migraine
|
March 5, 2021 | Phase 3 |
| NCT05216263 | Allergan |
Chronic Migraine
|
November 1, 2022 | Phase 3 |
| NCT05264129 | AbbVie |
Episodic Migraine
|
March 7, 2022 | Phase 4 |
| NCT03700320 | Allergan |
Episodic Migraine
|
October 8, 2018 | Phase 3 |
| NCT03939312 | Allergan |
Episodic Migraine
|
May 6, 2019 | Phase 3 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 100 mg/mL ( 165.69 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.6569 mL | 8.2847 mL | 16.5695 mL |
| 5 mM | 0.3314 mL | 1.6569 mL | 3.3139 mL |
| 10 mM | 0.1657 mL | 0.8285 mL | 1.6569 mL |